Know Cancer

or
forgot password

Zoledronic Acid (Zometa) for the Management of Tumor-induced Hypercalcemia (TIH) and Malignant Bone Pain (MBP) in the Community: A Feasibility Study


N/A
18 Years
N/A
Not Enrolling
Both
Cancer, Hypercalcemia, Pain

Thank you

Trial Information

Zoledronic Acid (Zometa) for the Management of Tumor-induced Hypercalcemia (TIH) and Malignant Bone Pain (MBP) in the Community: A Feasibility Study


Treatment in the home and hospice of long-term care facilities, particularly for
non-ambulatory patients, could provide significant advantages for patients and for the
region. The Calgary Health Region has a unique resource in the home parenteral therapy
program (HPTP). With the assistance of HPTP, patients requiring bisphosphonate treatment
for the management of TIH or MBP could be treated in the community (ie at home). However,
the resources required and the costs associated with community-based (homes, hospices,
long-term care facilities) treatment of TIH and MBP need to be identified and evaluated so
as to guide future regional decision making.


Inclusion Criteria:



If hypercalcemic:

- Serum corrected Ca+++>= 2.5 mmol/L and symptomatic hypercalcemia

- Asymptomatic hypercalcemia with corrected Ca+++>= 3.0 mmol/L

- Moderate to severe intolerable pain (>=6/10 on numerical rating scale [NRS]) despite
optimal treatments with a strong opioid such as morphine, hydromorphone, fentanyl,
oxycodone or methadone

- Radiotherapy bone pain related to metastatic bone disease

Exclusion Criteria:

- Not on a regular bisphosphonate regimen

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

feasibility of treating hypercalcemia in the community

Principal Investigator

Jose Pereira, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Alberta Cancerboard

Authority:

Canada: Health Canada

Study ID:

17280

NCT ID:

NCT00126386

Start Date:

January 2004

Completion Date:

September 2006

Related Keywords:

  • Cancer
  • Hypercalcemia
  • Pain
  • tumor induced hypercalcemia
  • malignant bone pain
  • bisphosphonates
  • cancer
  • palliative
  • Zometa
  • palliative patient
  • treatment in community
  • Hypercalcemia

Name

Location